Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2008

View Archived Issues

LY-450139 meets efficacy and safety endpoints in Alzheimer's disease phase II study

Abbott's ABT-869 shows activity against hepatocellular carcinoma in a phase II study

[188Re]-HDD-lipiodol studied for hepatocellular carcinoma in Mongolia

New data on bazedoxifene and bazedoxifene/CE in osteoporosis available

Regeneron and Columbia University sign agreement for VelocImmune mice

Pharmacopeia identifies new lead compound for advancement in alliance with GSK

Auxilium initiates dosing in phase IIb trial of Xiaflex in Peyronie's disease

Recent patent literature describes new anticancer agents

Omeros and The Parkinson's Institute sign collaboration to evaluate a molecular target in PD

Ovation acquires U.S. rights to Xenazine for chorea associated with HD

Merck Serono completes enrollment in REFLEX phase III trial of Rebif in MS

Memory and Roche expand R-3487/MEM-3454 development program

Sanofi pasteur sponsors MEL11 phase II clinical study of ALVAC vaccine in cancer

AMT and Amgen enter license agreement to develop gene therapy for PD

Merck & Co. discontinues license and research collaboration agreement with SurModics

Talecris signs exclusive license agreement with Crucell for PER.C6 technology

Interim results for a novel DNA plasmid BHT-3021 from a phase I/II type 1 diabetes study

Avigen completes multicenter AV-650 phase IIb spasticity trial in MS

EMEA recommends orphan drug designation for AX-200 in spinal cord injury

FDA issues complete response letter to Roche for Actemra BLA

New agents for treating neurological disorders disclosed in recent patents

Recent patents report novel treatments for obesity

Sanofi-aventis Europe intends to raise offer to acquire Zentiva

Enobia receives FDA orphan drug designation for ENB-0040 in hypophosphatasia

EMEA grants orphan drug designation to ATIR for graft-versus-host disease

KeyNeurotek receives EMEA orphan drug designation for KN-38-7271

Anisodamine eliminates NSAID-induced ulcers in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...